ABSTRACT Two experiments assessed the efficacy of in ovo administration of insulin-like growth factor-I (IGF-I) to enhance skeletal muscle development and improve feed efficiency of broilers. Hatching eggs were divided into three groups: uninjected control, vehicleinjected control, and recombinant human (rh) IGF-I (100 ng per embryo). Eggs in Experiment 1 were injected on Day 1, 4, or one of Day 7 through 18 of incubation. Growth rates for Days 1 and 4 resulted in the greatest response to treatment (P < 0.01, P < 0.06 respectively). Based on these results, Experiment 2 focused on Days 1 to 4 of incubation. Results from Experiment 2 showed that there was no significant difference in hatchability among control and rh IGF-I treatment groups. Injection on Day 3 resulted in the greatest response for increased live (P < 0.035) and leg (P < 0.02) weights in both sexes. Feed efficiencies of all rh IGF-I groups were significantly (P < 0.01) improved for the first 3 wk. In ovo administration of rh IGF-I on Day 3 increased feed efficiency (6.65%; P < 0.009) in pens of mixed-sex broilers. In addition, live weights (12.3%; P < 0.002), leg weights (11.7%; P < 0.01), breast weights (9.9%; P < 0.04), and heart weights (11.4%; P < 0.02) were increased in males. These results demonstrate that in ovo administration of rh IGF-I alters feed efficiency, growth, and tissue development. This finding lends itself to significant improvements in broiler production efficiency and profitability.
INTRODUCTION
Insulin-like growth factor-I (IGF-I) is a broadspectrum growth factor that stimulates DNA synthesis in over 20 cell types derived from endoderm, ectoderm, and mesoderm (Van Wyk, 1984) . Binding of recombinant human IGF-I (rh IGF-I) to high affinity type 1 IGF receptor stimulates proliferation, differentiation, and protein accretion in muscle cells isolated from hatching chickens (Duclos et al., 1991) . During embryonic chicken development, IGF-I is first expressed during the blastoderm stage (newly laid egg; Serrano et al., 1990) . During this period, secretion of IGF-I is independent of growth hormone (Kikuchi et al., 1991 , Tanaka et al., 1996 . The early expression of IGF-I suggests that this peptide plays a significant role in chicken embryo growth.
Growth retardation related to endogenous conditions with low IGF-I serum concentration was reversed by increasing circulating IGF-I in hypophysectomized rats (Schoenle et al., 1985; Zapf et al., 1989) and in snell dwarf mice (Van Buul-Offers et al., 1986) . However, whether the growth pattern of normal animals can be affected by increasing the circulating concentrations of IGF-I has not been fully elucidated. Although injection (s.c.) of rh IGF-I had a significant effect on body weight in young male rats after 7 d (Hizuka et al., 1987) , no altered growth response was observed in normal male rats following 6 d of injection (Zapf et al., 1989) . Additionally, injection (s.c.) of rh IGF-I by osmotic minipumps did not affect body weight in 4-wk-old female broilers (Huybretchs et al., 1992) and in 25-d-old broiler chickens (McGinness and Cogburn, 1991) .
Although injection of IGF-I on Day 2 stimulated organogenesis in the early chick embryo (Girbau et al., 1987) , it is not known whether the administration of IGF-I during embryonic development can stimulate postnatal growth and feed efficiency of broilers. For this reason, the objective of these experiments was to assess the efficacy of in ovo administration of rh IGF-I to enhance skeletal muscle development and improve feed efficiency of broiler chickens.
MATERIALS AND METHODS

Hatching Eggs
Fertilized eggs for Experiment 1 (Hubbard × Hubbard) and Experiment 2 (Hubbard × Ross) were obtained from the West Virginia University Poultry Facility and Wampler-Longacre, 2 respectively. In Experiment 1, 45 eggs (30 eggs per rh IGF-I treatment, 15 eggs per control group) were injected on Day 1, 4, or one of Day 7 through 18 of incubation (total of 630 eggs). Based on the results of the first experiment, 125 injected eggs (70 eggs per rh IGF-I treatment, 55 per control group), and 55 uninjected eggs were subjected to treatment on Day 1, 2, 3, or 4 of incubation (total 555 eggs) in the second experiment.
Injection Procedure
In ovo administration of either rh IGF-I 3 or vehicle (10 mM acetic acid, 0.1 g BSA in 100 mL) at 100 mL per egg was performed through the blunt end of the eggs. Recombinant human IGF-I was diluted in vehicle at 100 ng/ 100mL and was stored at -20 C. Prior to injection, the blunt end of the egg was sterilized with 70% ethanol. A single hole was created with a dental drill bit without penetrating the chorio-allantoic membrane. Both rh IGF-I (100 ng per egg) and vehicle were injected into the albumen with a 22-gauge needle. The hole was sealed with an adhesive sticker. Eggs were set in a Buckeye incubator/hatcher 4 (temperature 37 ± 0.5 C, humidity 86 to 87%).
Pen Assignment and Experimental Design
At hatching, chicks were vaccinated for Marek's Disease (s.c. in the neck; 0.2 cc per chick) and separated by feather sexing. All chicks, depending on their treatment group, were randomly assigned to different pens. In Experiment 2, nine treatment groups (four treatments; four treatment-controls; one uninjected control group) were replicated in triplicate and were randomly placed in 27 pens. Each replicate consisted of approximately 20 chicks each (10 male + 10 female). The experimental design was similar to a split-plot design in which pen was the whole plot and chicken was the subplot.
During the first 3 wk, chicks were fed a starter ration that contained 21.2% protein and 3,080 kcal/kg metabolizable energy. Feed and water were available for ad libitum consumption. During the last 3 wk of production, birds were fed a grower ration that contained 19.5% protein and 3,124 kcal/kg metabolizable energy. Chickens were housed in a thermostatically controlled building with a 24 h lighting schedule.
Pen weight and mortality were recorded weekly. Average feed consumption and feed to gain ratios per pen were determined weekly. At the end of the treatment period (42 d of age), treatment groups were selected for further analysis according to their feed efficiency and live weight improvement. Day 3 treatment (n = 22) and uninjected (n = 16) as well as associated control (n = 22) groups for a total of 60 chicks were selected for further processing. Whole body, breast muscle (both breasts + rib cage), liver, heart, and leg (leg + thigh) data were collected. Individual tissue or organ weights were recorded. Right shank length for each chick was measured by calipers on the cranial side of tibia. Broilers remaining from the selected groups (n = 58) were euthanatized on the following day for whole carcass analysis.
Proximate Analysis
Carcasses (without neck, feet, viscera, skin, and feathers) were chilled in a cold room for 2 h and then frozen for analysis of body composition. Frozen carcasses were cut into 2.5-cm strips using a band saw (Model 33), 5 and strips were mixed. Whole frozen carcasses were ground twice through a 3.2-mm plate in a meat grinder (Model 5). 5 Approximately 150 g of ground sample was randomly collected for moisture, protein, fat, and ash analyses (AOAC, 1990) . These samples were frozen in liquid nitrogen and subsequently powdered in a prechilled stainless steel Waring blender. 6 Powdered samples were stored at -20 C prior to analysis.
Texture Analysis
Pectoralis profundus was removed from each chicken and cooked to 80 C internal temperature on a Farberware Smokeless Indoor Grill. 7 Right or left sides were randomly chosen. A Beckman Industrial Datalogger 8 was used to monitor internal cooking temperature. To determine percentage cook yield, raw and cooked weights were recorded. After cooked muscle was cooled to room temperature, 1.27-cm-thick slices were cut perpendicular to the fiber orientation of the muscle and two or three 1.27-cm-diameter cores were removed from each strip (Kenney et al., 1996) . An Instron Universal Testing Machine, 9 equipped with a Warner-Bratzler shear force attachment (Model 1520.50), 10 was used for shear force determination. Warner-Bratzler shear force was determined by a cross head speed of 127 mm/min. Output was recorded via a Daytronic main frame equipped with a LVDT conditioner (Model 9130), 10 and output from the main frame was sent to a computer equipped with a DT 2805 data acquisition board. 11 TABLE 1. Average mixed-sex broiler weights from Experiment 1 (n = 30 for each treatment group, n = 15 for each vehicle injected control group; weekly, kg)
1 Vehicle-injected control group. *P < 0.06 compared with respective control groups. **P < 0.01 compared with respective control groups. 
Day of incubation
Statistical Analysis
Analysis of variance was performed by the GLM procedures of SAS ® (SAS Institute, 1989). The Least Significant Difference test was used to compare the means. The CATMOD test was used to compare hatchability of chickens. Statements of significance were based on P < 0.05 unless otherwise noted.
RESULTS
In Experiment 1, administration of rh IGF-I on Day 1 or 4 resulted in an increase in the body weight of 42-d-old chickens (Table 1) , whereas injection on one of Day 7 through 18 of incubation was without effect. Injection on Day 1 of incubation showed the greatest response in terms of body weight (P < 0.01; Table 1 ). Because of the growth responses observed in the first experiment, the second experiment focused on Day 1 through 4 of incubation.
Hatchability was decreased by the injection procedure with either vehicle or rh IGF-I compared to 93% in uninjected chicks (Table 2) . However, there was no difference in hatchability between control and rh IGF-I treatment groups on the same injection day (Table 2) . In ovo administration of either rh IGF-I or vehicle on Day 2 reduced hatchability of broilers (62%; P < 0.05; Table 2 ).
Measurements of Growth Performance
Beginning at 2 wk posthatch, average weights were greater in treated groups (Table 3) . During the growout period, eggs administered in ovo rh IGF-I on Day 3 showed the greatest improvement in feed efficiency of mixed-sex broilers at each sampling time during the study (Figure 1 ) with an improvement of 6.65% (P < 0.009) at the end of 6 wk. Additionally, Day 3 injection resulted in the greatest response for live weights (P < 0.035) and leg weights (P < 0.02) in the mixed-sex broilers. Feed conversion ratios of all rh IGF-I groups were (P < 0.01) greater for the first 3 wk of production as compared to controls (Figure 1) . In all groups, feed conversion varied for the first 3 wk after hatch and then remained at a plateau level for the duration of the study. A treatment by sex effect was observed in rh IGF-I Day 3 groups. In males, there was an increase in live weights (12.3%; P < 0.002), leg weights (11.7%; P < 0.01), breast weights (9.9%; P < 0.04), and heart weights (11.4%; P < 0.02; Figure 2 and Table 4 respectively), whereas in females there was an improvement in shank length (4.7%; P < 0.02; Table 4 ). There was a sex effect for all parameters measured except for liver weights in control and shear force in treated groups (Table 4) .
Carcass Analyses
No significant differences were observed between Day 3 treatment, control, and uninjected groups for fat, protein, ash, and moisture (Table 5) . However, male chickens in all treatment and uninjected control groups were leaner than their female counterparts (Table 5) . Also, Warner-Bratzler shear force was not affected by Day 3 injection when compared to controls (Table 4 ). There were no significant differences between the uninjected group and the treatment control groups in terms of any growth measurement or feed conversion. There were no pen effects between treatment and control groups. 
DISCUSSION
Results of the first experiment (Table 1) concurred with results of Spencer et al. (1990) , who demonstrated that administration of exogenous IGF-I (500 ng per embryo) to the chick embryo on Day 7 and 14 did not stimulate development and postnatal growth of the chicks. One possible reason for lack of postnatal growth stimulation by IGF-I injection during the mid-incubation phase is that endogenous IGF-I production in the normal chick embryo may be sufficient to allow maximal growth. Serum IGF-I concentration at Days 7 to 14 of incubation is less than 20 ng/mL (Kikuchi et al., 1991) . The yolk of an unfertilized chicken egg has approximately 0.18 to 0.8 ng/mL IGF-I (Scavo et al., 1989) , whereas the volume of a chicken egg is approximately 75 mL. Therefore, after injection, the basal levels of IGF-I were increased by approximately 1.33 ng/mL (100 ng/75 mL) in this study. Additionally, Florini et al. (1986) reported that myoblast differentiation in L6 cell culture was inhibited at high IGF-I concentrations (more than 100 ng/mL). For this reason we selected a lower in ovo recombinant human (rh) insulin-like growth factor (IGF)-I on heart, liver weights, texture analysis,  and shank length of 42-d-old broilers from Experiment 2 (x ± SEM, n = 11 for each sex in each treatment and control group) 1 Recombinant human insulin-like growth factor-I. 2 Vehicle-injected control group (M = male, F = female). *P < 0.05 compared within a column. **P < 0.02 compared within a column.
Injection day
Heart weight Liver weight Shank length Texture analysis
Day 3 13.7 ± 0.4** 10.8 ± 0.3 55.7 ± 2.7 48.4 ± 2.3 108.4 ± 1.6 100.6 ± 1.3* 2,876 ± 472.6 2,369 ± 431.5 Control 2 Day 3 12.3 ± 0.4 10.4 ± 0.4 52.4 ± 2.5 52.2 ± 2.6 108.4 ± 1.4 96.1 ± 1.5 3,076 ± 431.5 2,083 ± 472.6 11.2 ± 0.8 17.6 ± 0.3 2.4 ± 0.1 66.4 ± 0.6 Female 12.9 ± 0.8 17.3 ± 0.3 2.3 ± 0.1 65.7 ± 0.6 Control 2 Day 3 Male 11.5 ± 0.6 17.3 ± 0.2 2.6 ± 0.1 66.5 ± 0.5 Female 11.9 ± 0.6 17.4 ± 0.2 2.4 ± 0.1 66.3 ± 0.5 dose to mimic physiological concentrations of IGF-I during mid-incubation. In Experiment 2, in ovo administration of rh IGF-I (100 ng per embryo) increased growth and feed efficiency of broilers. In Experiment 1, early administration of rh IGF-I (Day 1 or 4) produced the most positive effects (Table  1) , whereas injection on one of Day 7 through 18 of incubation did not affect body weights of chicks. Moreover, injection on Day 1 resulted in the greatest response for live weights. In comparison with Experiment 1, injection on Day 3 in the second experiment resulted in the greatest response. Varied response to early injection could be due to differences in the strains of chickens used in Experiment 1 and 2 (Hubbard × Hubbard, Hubbard × Ross, respectively). In addition, the effects of injection on Day 2 or 3 were not investigated in the first experiment. In Experiment 1, injection on Day 13 inhibited 6-wk growth compared to control groups (treatment, 1.961 kg; control, 1.971 kg). This result could be due to expression of the sex related hormones such as estrogen and testosterone during this developmental stage . Possible reasons for the observed differences in rh IGF-I effects may include variations in the expression patterns of insulin-like growth factor binding proteins, growth hormone, or a cross-reaction between insulin and IGF-I receptors.
In terms of injection time, our results agree with the results obtained by Girbau et al. (1987) . They injected eggs at Day 2 of embryonic development (10 to 100 ng rh IGF-I per embryo) and found a significant increase in general development and growth (such as weight, total protein, DNA, RNA, and total creatine kinase) of 4-d-old chicken embryos. However, their studies were limited to a 2-d time period during embryonic development, whereas our study followed changes through 42 d posthatch. Additionally, we did not find any significant difference between the uninjected group and the treatment control groups in terms of any growth measurement or feed conversion. These results indicate that the in ovo injection procedure per se did not affect any of the respective changes in development.
Daily injection of 200 mg/kg of rh IGF-I from 11 to 24 d of age reduced body ash content of 25-d-old broiler chicks (McGuinness and Cogburn, 1991) . Huybrechts et al. (1992) demonstrated that implantation of osmotic minipumps in 4-wk-old female broiler chickens to supply a 2-wk continuous infusion of rh IGF-I in three doses (0.03, 0.1, and 0.3 mg/kg BW per d) did not have a significant effect on body weight. On the other hand, they found that abdominal fat was significantly reduced at the highest doses. They suggested that injection of rh IGF-I during the posthatch period reduced fat and ash content of the broiler chicks. However, we found no significant differences among treatments for moisture, fat, protein, or ash content. The lack of effect of treatment on these variables suggests that the timing of IGF-I is an important factor determining carcass composition. Different mechanisms are likely involved during these different developmental stages.
In ovo administration of rh IGF-I (100 ng per embryo) on Day 3 of embryonic development significantly increased skeletal muscle growth of broiler chicks. During the posthatch phase, chicks that had accelerated muscle growth demonstrated improved feed efficiency. Administration on Day 3 corresponds to myodermal migration and a period of substantial development of the dorsomedial portion of somites, the portion that gives rise to the origin of skeletal muscle (Chevallier, 1979; Schramm and Solursh, 1990; Ordahl and Douarin, 1992) . Whether there is a change in somite migration and division during embryonic development after administration of IGF-I during this time period remains to be investigated.
It is widely accepted that IGF-II may be the somatomedin involved in growth promotion in the mammalian fetus (Moses et al., 1980) . Whereas type-II receptors for IGF-II are absent in the chick embryo (Bassas et al., 1988) , IGF-II circulates in chickens at concentrations similar to those in mammals (Czech, 1989) . Although IGF-II receptor is not present in avian ovarian tissue (Roberts et al., 1994) , IGF-II stimulates DNA synthesis and cell proliferation in thecal and granulosal cells (Onagbesan et al., 1994) . IGF-II most likely exerts its biological effect in avian cells through the IGF-I receptor (Kasuga et al. 1982) . Therefore, comparable studies on the effects of administration of IGF-II could be of interest.
Another possible explanation for the growth response includes the induction of the myogenic regulatory gene family, which plays a major role in muscular hyperplasia, because it is activated very early in mammalian embryogenesis at the myotomal and limb bud stages. It is well known that IGF-I stimulates myogenin gene expression in L6A1 muscle cell culture (Florini et al., 1991) . Additional studies should be conducted to determine whether hypertrophic or hyperplastic skeletal muscle growth are predominant during embryonic and posthatch chicken development of the IGF-I injected groups. The influence of in ovo IGF-I administration on muscle fiber type selection and metabolism also needs to be investigated. Additionally, because IGF-I affects bone growth, changes in bone metabolism and mineralization could be of interest.
Our results indicate that in ovo administration of rh IGF-I improves the feed efficiency, growth and tissue development of posthatch broiler chicks. Increased weight was found in economically important tissues (breast and leg) with no adverse affects on tenderness. Taken together, this approach may provide a means of providing significant improvements in the rate and efficiency of broiler production.
